This white paper provides biotech companies an overview of the considerations for Chemistry, Manufacturing and Controls (CMC) in asset development. There are a multitude of complexities and points to consider when developing an asset, and product development is at the center of all development. Selection of the right development partner, who has experts in all aspects of CMC, is a critical first step as an asset is developed. The right development partner can ensure there is a consistent ‘end-to-end’ process and continuity in the development of your asset.
In this paper, you will learn about:
- CMC Considerations
- Why CMC is a critical component in drug development
- Why it is important to identify issues early
- Why CMOs are critical to success
Explore related content and topics
White Paper
Pediatric Product Development Plan
Development of the Pediatric Study Plan (PSP) for the United States Food and Drug Administration and the Pediatric Investigation Plan (PIP) for the…
White Paper
How to Successfully Navigate Orphan Drug Designation
An orphan designation may add value to a product by potentially increasing stock value, increasing the company visibility, and initiating early…
White Paper
New Agency Liaison Opportunity in the EU
Scientific advice is a regulatory process expected to, “facilitate timely access to safe and efficacious medicinal products to patients and users of…